glp-1 substance use disorder GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and intake, though GLP-1 medication treats addiction in

The FDA issued guidance stating that 503A compounding pharmacies had until April 22, 2025 to stop producing semaglutide injection products that were essentially copies of the commercially available drug

Understanding the balance among diet, lifestyle, and supplementation is key to effectively managing GLP-1-related health outcomes

However, absorption often declines with age and can be impaired by digestive conditions (such as IBS, Crohns, or coeliac disease) and by certain medications (for example, long-term use of proton pump inhibitors)

Endocrine disrupting chemicals: effects on endocrine glands

This powerful antioxidant boosts your bodys defenses by increasing the production and activity of your white blood cells, which are essential in fighting off infections

More than 4 million items of tirzepatide and semaglutide were dispensed on the NHS in England in 2025/2026 1 , while around 2.5 million people each month accessed GLP-1s privately at the end of 2025, according to James Kingsland, chair of the Digital Clinical Excellence (DiCE) network of primary care digital health providers